Annuncio pubblicitario
Italia markets close in 5 hours 6 minutes
  • FTSE MIB

    34.275,12
    +335,37 (+0,99%)
     
  • Dow Jones

    38.085,80
    -375,12 (-0,98%)
     
  • Nasdaq

    15.611,76
    -100,99 (-0,64%)
     
  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     
  • Petrolio

    83,88
    +0,31 (+0,37%)
     
  • Bitcoin EUR

    60.017,61
    +785,51 (+1,33%)
     
  • CMC Crypto 200

    1.392,49
    -4,05 (-0,29%)
     
  • Oro

    2.360,40
    +17,90 (+0,76%)
     
  • EUR/USD

    1,0734
    +0,0001 (+0,01%)
     
  • S&P 500

    5.048,42
    -23,21 (-0,46%)
     
  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     
  • Euro Stoxx 50

    4.971,91
    +32,90 (+0,67%)
     
  • EUR/GBP

    0,8574
    +0,0000 (+0,00%)
     
  • EUR/CHF

    0,9787
    +0,0002 (+0,02%)
     
  • EUR/CAD

    1,4654
    +0,0005 (+0,04%)
     

Why AstraZeneca May Dominate the European Vaccine Market

Demand in the U.S. might be limited, since President Joe Biden recently bought enough vaccine doses from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) to vaccinate nearly all Americans. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss opportunity in Europe and why AstraZeneca might have an advantage.